Aug 04, 2022 07:08 AM IST

Hot Stocks | Here is why you should bet on Dr Lal PathLabs and TCS for short term

Dr Lal PathLabs witnessed an ascending triangle pattern breakout on July 29 which was placed above Rs 2,250 levels in the daily time frame. After breakout, prices are showing a gradual upside movement in a small steep formation.

We are focussed on productivity, says Dr Lal PathLabs MD

On the firm’s Q1FY23 numbers, Om Manchanda said the diagnostics chain's legacy business was up 15% YoY

Dr Lal PathLab Consolidated June 2022 Net Sales at Rs 502.70 crore, down 17.13% Y-o-Y

Dr Lal PathLab Standalone June 2022 Net Sales at Rs 439.30 crore, down 22.23% Y-o-Y

Trade Spotlight | What should you do with InterGlobe Aviation, Dr Lal PathLabs, M&M Financial on Friday?

On daily charts, M&M Financial has formed long bullish candle which is broadly positive for the M&M Finance. Unless it is trading below Rs 165 or 200 days SMA, positional traders retain an optimistic stance and look for a target Rs 185-195.

Dr Lal Pathlab misses Q4 estimates; shares hit 19-month low

The stock dropped to Rs 2022.55 apiece today- a level last seen on 16 October 2020. This is the fourth consecutive session where the stock has been trading in the red zone.

Dr Lal PathLab Consolidated March 2022 Net Sales at Rs 485.50 crore, up 12.65% Y-o-Y

Dr Lal PathLab Standalone March 2022 Net Sales at Rs 414.90 crore, up 2.67% Y-o-Y

Top 10 trading ideas by experts for next 3-4 weeks as bulls firm up control over Dalal Street

Traders can look to trade with a positive bias and buy Reliance Industries in the range of Rs 2,460-2,450 for a potential target of Rs 2,600 in the near term. One should place a stop-loss below Rs 2,380 on long positions

Dr Lal PathLab Consolidated December 2021 Net Sales at Rs 496.90 crore, up 9.84% Y-o-Y

Dr Lal PathLab Standalone December 2021 Net Sales at Rs 422.50 crore, down 1.08% Y-o-Y

Trade Spotlight | What should you do with Dr Lal PathLabs, Spandana, Elgi Equipments, VIP Industries, Capri Global?

Trade Spotlight | Here's what Mehul Kothari of Anand Rathi Shares & Stock Brokers, recommends investors should do with these stocks when the market resumes trading today

Top 12 trading ideas for January series as market keeps a watch on Omicron

Sameet Chavan of Angel One says Traders should trade with a positive bias as long as the index remains above 17,000–16,800

Hot Stocks | Here's why you should bet on TCS, Dr Lal PathLabs, Max Healthcare Institute for short term

Shitij Gandhi of SMC Global Securities expects markets to remain under pressure in upcoming sessions as well and likely to trade on volatile path.

Dr Lal Pathlab – Suburban Diagnostic deal - a marriage made in a Petri dish

Inorganic growth in this sector has been the norm across the globe, and most countries in the developed world have 5-6 large players dominating the space

Dr Lal PathLab Consolidated September 2021 Net Sales at Rs 498.40 crore, up 15.4% Y-o-Y

Dr Lal PathLab Standalone September 2021 Net Sales at Rs 470.40 crore, up 16.35% Y-o-Y

Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher

Net Sales are expected to increase by 26.8 percent Y-o-Y (down 9.7 percent Q-o-Q) to Rs 547.6 crore, according to Prabhudas Lilladher.

Dr Lal PathLab Consolidated June 2021 Net Sales at Rs 606.60 crore, up 128.05% Y-o-Y

Dr Lal PathLab Standalone June 2021 Net Sales at Rs 564.90 crore, up 121.53% Y-o-Y

Dr Lal PathLabs Q1 net profit zooms nearly 5-fold to Rs 133.7 crore

The company had posted a net profit of Rs 28.4 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a regulatory filing.

Dr Lal PathLabs Q4 net profit jumps over 2.5 times to Rs 85.1 crore

The company had posted a net profit of Rs 32.6 crore for the corresponding period of the previous financial year, Dr Lal PathLabs said in a regulatory filing.

Emerging healthcare trends put diagnostics sector in a sweet spot, IIFL Sec recommends buy on Metropolis, Thyrocare

Larger players from the diagnostic sector are positioned to gain more than the smaller ones and fragmented market share is an opportunity for them to expand their share.

Dr Lal PathLab Standalone December 2020 Net Sales at Rs 427.10 crore, up 37.6% Y-o-Y

Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 16.1 percent Y-o-Y (down 11.8 percent Q-o-Q) to Rs. 327.9 crore, according to Prabhudas Lilladher.